


# PRODUCT INFORMATION



**SB-207266**

Item No. 18778

**CAS Registry No.:** 152811-62-6  
**Formal Name:** N-[(1-butyl-4-piperidiny)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide  
**Synonym:** Piboserod  
**MF:** C<sub>22</sub>H<sub>31</sub>N<sub>3</sub>O<sub>2</sub>  
**FW:** 369.5  
**Purity:** ≥95%  
**UV/Vis.:** λ<sub>max</sub>: 224, 263, 294 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

SB-207266 is supplied as a crystalline solid. A stock solution may be made by dissolving the SB-207266 in the solvent of choice. SB-207266 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of SB-207266 in DMSO is approximately 20 mg/ml and approximately 30 mg/ml in ethanol and DMF.

SB-207266 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, SB-207266 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. SB-207266 has a solubility of approximately 0.05 mg/ml in a 1:20 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

## Description

The indole derivative SB-207266 is a selective and potent antagonist of the serotonin (5-HT) receptor 5-HT<sub>4</sub> with a pA<sub>2</sub> value of 10.6 ± 0.1.<sup>1,2</sup> In COS7 cells, 100 nM SB-207266 inhibited 5-HT<sub>4</sub> responses to 5-HT and reduced basal agonist-independent cAMP production.<sup>2</sup> In several animal models, low concentrations of SB-207266 blocked exogenous 5-HT-mediated sensitization of intestinal peristalsis.<sup>1,3,4</sup> In a dog model, SB-207266 (0.1–100 pg/kg) dose-dependently reduced responses to 5-HT, with an ID<sub>50</sub> value of 1.3 pg/kg.<sup>1</sup> SB-206226 (0.5 mg/kg/24 h) improved cardiac function in a rat model of congestive heart failure.<sup>5</sup>

## References

1. Wardle, K.A., Bingham, S., Ellis, E.S., et al. *Br. J. Pharmacol.* **118**(3), 665-670 (1996).
2. Claeysen, S., Sebben, M., Bécamel, C., et al. *Mol. Pharmacol.* **58**(1), 136-144 (2000).
3. Sanger, G.J., Yoshida, M., Yahyah, M., et al. *Br. J. Pharmacol.* **130**(3), 706-712 (2000).
4. Ellis, M., Chambers, J.D., Gwynne, R.M., et al. *Am. J. Physiol. Gastrointest. Liver Physiol.* **304**(8), G749-G761 (2013).
5. Birkeland, J.A.K., Sjaastad, I., Brattelid, T., et al. *Br. J. Pharmacol.* **150**(2), 143-152 (2007).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/15/2022

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM